APPLIED ASPECTS OF SLCO1B1 PHARMACOGENETIC TESTING FOR PREDICTING OF STATIN-INDUCED MYOPATHY AND PERSONALIZATION OF STATINS THERAPY

Documenti analoghi

• APPLIED ASPECTS OF SLCO1B1 PHARMACOGENETIC TESTING FOR PREDICTING OF STATIN-INDUCED MYOPATHY AND PERSONALIZATION OF STATINS THERAPY
  di: D. A. Sychev, et al.
  Pubblicazione: (2015-09-01)
• The frequency of SLCO1B1*5 polymorphism genotypes among Russian and Sakha (Yakutia) patients with hypercholesterolemia
  di: Sychev DA, et al.
  Pubblicazione: (2016-05-01)
• THE SLCO1B1 GENE POLYMORPHISM AND STATIN-INDUCED MYOPATHY IN RUSSIAN PATIENTS
  di: V. I. Petrov, et al.
  Pubblicazione: (2014-10-01)
• Clinical case of statin-induced myopathy in female patient with compensated hypothyroidism and unfavorable polymorphic variant of SLCO1B1*5 (c.521T>C)
  di: Liya A. Lugovaya, et al.
  Pubblicazione: (2021-05-01)
• Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy
  di: N A Rumyantsev, et al.
  Pubblicazione: (2017-01-01)